NASDAQ
GLPG

Galapagos NV ADR

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Galapagos NV ADR Stock Price

Vitals

Today's Low:
$36.05
Today's High:
$36.85
Open Price:
$36.85
52W Low:
$36.05
52W High:
$49.59
Prev. Close:
$36.68
Volume:
114771

Company Statistics

Market Cap.:
$2.44 billion
Book Value:
1.9606
Revenue TTM:
$560.14 million
Operating Margin TTM:
-28.34%
Gross Profit TTM:
$4.82 million
Profit Margin:
-28.09%
Return on Assets TTM:
-2.08%
Return on Equity TTM:
-6.02%

Company Profile

Galapagos NV ADR had its IPO on 2005-05-06 under the ticker symbol GLPG.

The company operates in the Healthcare sector and Biotechnology industry. Galapagos NV ADR has a staff strength of 1,233 employees.

Stock update

Shares of Galapagos NV ADR opened at $36.85 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $36.05 - $36.85, and closed at $36.13.

This is a -1.5% slip from the previous day's closing price.

A total volume of 114,771 shares were traded at the close of the day’s session.

In the last one week, shares of Galapagos NV ADR have slipped by -5.07%.

Galapagos NV ADR's Key Ratios

Galapagos NV ADR has a market cap of $2.44 billion, indicating a price to book ratio of 0.9452 and a price to sales ratio of 4.5411.

In the last 12-months Galapagos NV ADR’s revenue was $560.14 million with a gross profit of $4.82 million and an EBITDA of $-134771008. The EBITDA ratio measures Galapagos NV ADR's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Galapagos NV ADR’s operating margin was -28.34% while its return on assets stood at -2.08% with a return of equity of -6.02%.

In Q2, Galapagos NV ADR’s quarterly earnings growth was a positive 2053.6% while revenue growth was a positive 9%.

Galapagos NV ADR’s PE and PEG Ratio

Forward PE
81.3008
Trailing PE
0
PEG
0

Its diluted EPS in the last 12-months stands at $-2.55 per share while it has a forward price to earnings multiple of 81.3008 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Galapagos NV ADR’s profitability.

Galapagos NV ADR stock is trading at a EV to sales ratio of 1.1836 and a EV to EBITDA ratio of -28.9095. Its price to sales ratio in the trailing 12-months stood at 4.5411.

Galapagos NV ADR stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$4.52 billion
Total Liabilities
$475.07 million
Operating Cash Flow
$0
Capital Expenditure
$3.81 million
Dividend Payout Ratio
0%

Galapagos NV ADR ended 2024 with $4.52 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $4.52 billion while shareholder equity stood at $2.58 billion.

Galapagos NV ADR ended 2024 with $0 in deferred long-term liabilities, $475.07 million in other current liabilities, 293937000.00 in common stock, $-440792000.00 in retained earnings and $69.68 million in goodwill. Its cash balance stood at $98.02 million and cash and short-term investments were $3.87 billion. The company’s total short-term debt was $6,210,000 while long-term debt stood at $0.

Galapagos NV ADR’s total current assets stands at $4.03 billion while long-term investments were $0 and short-term investments were $3.78 billion. Its net receivables were $67.58 million compared to accounts payable of $131.07 million and inventory worth $48.87 million.

In 2024, Galapagos NV ADR's operating cash flow was $0 while its capital expenditure stood at $3.81 million.

Comparatively, Galapagos NV ADR paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$36.13
52-Week High
$49.59
52-Week Low
$36.05
Analyst Target Price
$46.57

Galapagos NV ADR stock is currently trading at $36.13 per share. It touched a 52-week high of $49.59 and a 52-week low of $49.59. Analysts tracking the stock have a 12-month average target price of $46.57.

Its 50-day moving average was $39.88 and 200-day moving average was $40.62 The short ratio stood at 6.79 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 3158% are held by institutions.

Frequently Asked Questions About Galapagos NV ADR

The stock symbol (also called stock or share ticker) of Galapagos NV ADR is GLPG

The IPO of Galapagos NV ADR took place on 2005-05-06

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$62.39
0.03
+0.05%
$54.64
-1.87
-3.31%
Jindal Saw Limited (JINDALSAW)
$334.45
-49.9
-12.98%
$25.5
-0.39
-1.51%
$41.69
0
0%
$30.62
-0.07
-0.23%
$36.93
5.42
+17.2%
$0.19
-0
-0.52%
$329.65
-5
-1.49%
$6.52
-0.21
-3.12%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of”various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG3667 that has completed Phase 1b trial; and GLPG5101 and GLPG5201, CD19 CAR-T product candidate manufactures at point-of-care, that is in Phase I/II in relapsed/refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Address

Generaal De Wittelaan L11 A3, Mechelen, Belgium, 2800